Table 5 Participants with neuropathy symptoms frequency in both groups at the baseline and 4, 8, and 12Â weeks
Outcome measure | Baseline | 4Â weeks | 8Â weeks | 12Â weeks | ||
|---|---|---|---|---|---|---|
Magnet (n = 32) No. (%) | Localization | Feet | 31 (96.9) | 30 (93.8) | 23 (71.9) | 8 (25) |
Lower leg | 1 (3.1) | 2 (6.3) | 7 (21.9) | 11 (34.4) | ||
Elsewhere | 0 (0) | 0 (0) | 2 (6.3) | 13 (40.6) | ||
Exacerbation | Night | 22 (68.8) | 20 (62.5) | 4 (12.5) | 0 (0) | |
Day | 0 (0) | 0 (0) | 4 (12.5) | 17 (53.1) | ||
Day and night | 10 (31.3) | 12 (37.5) | 24 (75) | 15 (46.9) | ||
Symptom improvement | Walking | 11 (34.4) | 10 (31.3) | 5 (15.6) | 2 (6.3) | |
Standing | 0 (0) | 0 (0) | 0 (0) | 1 (3.1) | ||
Sitting or lying down | 21 (65.6) | 22 (68.8) | 27 (84.4) | 29 (90.6) | ||
Sham (n = 32) No. (%) | Localization | Feet | 31 (96.9) | 31 (96.9) | 31 (96.9) | 31 (96.9) |
Lower leg | 1 (3.1) | 1 (3.1) | 1 (3.1) | 1 (3.1) | ||
Exacerbation | Night | 14 (43.8) | 15 (46.9) | 20 (62.5) | 19 (59.4) | |
Day | 1 (3.1) | 0 (0) | 0 (0) | 0 (0) | ||
Day and night | 17 (53.1) | 17 (53.1) | 12 (37.5) | 13 (40.6) | ||
Symptom improvement | Walking | 10 (31.3) | 10 (31.3) | 10 (31.3) | 10 (31.3) | |
Sitting or lying down | 22 (68.8) | 22 (68.8) | 22 (68.8) | 22 (68.8) | ||
P value | ||||||
|---|---|---|---|---|---|---|
Localization | 1.00 | 0.01a |  < 0.001a | |||
Exacerbation | 0.31 |  < 0.001a |  < 0.001a | |||
Symptom improvement | 1.00 | 0.23 | 0.02a | |||